Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer

Lung Cancer

Volumn 53, Issue 2, 2006, Pages 205-210

  Antoniou, Dimosthenis ^a   Pavlakou, Georgia ^a   Stathopoulos, George P ^b   Karydis, Ioannis ^a   Chondrou, Evangelia ^a   Papageorgiou, Chrysovalantis ^a   Dariotaki, Fotini ^a   Chaimala, Dimitra ^a   Veslemes, Marinos ^a  

^a SOTIRIA GENERAL HOSPITAL   (Greece)

^b Errikos Dunant Hospital   (Greece)

Author keywords

Chemotherapy; D dimer; Lung cancer

Indexed keywords

CISPLATIN; D DIMER; DEXAMETHASONE; DOCETAXEL; ETOPOSIDE; GEMCITABINE; IRINOTECAN; NAVELBINE; ONDANSETRON; PACLITAXEL; PLASMA PROTEIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD CHEMISTRY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DISEASE COURSE; DISEASE MARKER; DRUG HYPERSENSITIVITY; DRUG RESPONSE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SENSORY DYSFUNCTION; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PACLITAXEL; PATIENT COMPLIANCE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VINBLASTINE;

EID: 33745612028     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.03.015     Document Type: Article

References (24)

1. Wakl W.L., Ahrns K.S., Zajkowski P.J., et al. Normal D-dimers levels do not exclude thrombotic complications in trauma patients. Surgery 134 4 (2003) 529-532
2. Shilon Y., Shitrit A.B., Rudensky B., et al. A rapid quantitative D-dimers assay admission correlates with the severity of community-acquired pneumonia. Blood Coagul Fibrinolysis 14 8 (2003) 745-748
3. Clavolella M., Tavolaro R., Di Loreto M., et al. Immunoscintigraphy of venous thrombi: clinical effectiveness of a new antifibrin D-dimer monoclonal antibody. Angiology 50 2 (1999) 103-109
4. So A.K., Varisco P.A., Kemkes-Matthes B., et al. Arthritis is linked to local and systemic activation of coagulation and fibrinolysis pathways. Thromb Haemost 1 12 (2003) 2510-2515
5. Atlarbaschi A., Mann G., Kronberger M., et al. Effects of dose-reduced Medac l-asparaginase on coagulation in trial ALL-BFM 2000. Klin Padiatr 215 6 (2003) 321-326
6. Trousseau A. Phlegmasia alba doleus. Clinique medicale de I'Hôtel-Dieu de Paris. 3rd ed. (1865), J.B. Balliere et Fils, Paris p. 654-712
7. Edwards R.L., Rickles F.R., Moritz T.E., et al. Abnormalities of blood coagulation tests in patients with cancer. Am J Clin Pathol 88 (1987) 596-602
8. Bick R.L. Coagulation abnormalities in malignancy: a review. Semin Thromb Hemost 18 (1992) 353-372
9. Rickles F.R., and Edwards R.L. Activation of blood coagulation in cancer, Trousseau's syndrome revisited. Blood 62 (1983) 14-31
10. Kwaan H.C., and Keer H.N. Fibrinolysis and cancer. Semin Thromb Hemost 16 (1990) 230-235
11. Gouin-Thibault I., and Samana M.M. Laboratory diagnosis of the thrombophilic state in cancer patients. Semin Thromb Hemost 25 (1999) 167-172
12. Rickles F.R., Levine M.N., and Dvorak H.F. Abnormalities of hemostasis in malignancy. In: Colman R.W., Hirsh J., Marder V.J., Clowes A.W., and George J.N. (Eds). Hemostasis and thrombosis. Basic principles and clinical practice. 4th ed. (2001), Lippincott Williams and Wilkins, Philadelphia 1131-1152
13. Guadagni F., Ferroni P., Basili S., et al. Correlation between tumor necrosis factor-alpha and D-dimer levels in non-small-cell lung cancer patients. Lung Cancer 44 (2004) 303-310
14. Roussell M., Mineo T.C., Basili S., et al. Vascular endothelial growth factor (VEGF-A) plasma levels in non-small-cell lung cancer: relationship with coagulation and platelet activation markers. Thromb Haemost 89 (2003) 177-184
15. Pavey S.J., Hawson G.A., and Marsh N.A. Alterations to the fibrinolytic enzyme system in patients with non-small-cell lung carcinoma. Blood Coagul Fibrinolysis 10 (1999) 261-267
16. Beer J.H., Haeberli A., Vogt A., et al. Coagulation markers predict survival in cancer patients. Thromb Haemost 88 (2002) 745-749
17. Buccheri G., Torchio P., and Ferrigno P. Plasma levels of D-dimer in lung carcinoma- clinical and prognostic significance. Cancer 97 (2002) 3044-3052
18. Ünsul E., Atalav F., Atikcan S., and Yilmaz A. Prognostic significance of hemostatic parameters in patients with lung cancer. Respir Med 98 (2004) 93-98
19. ten Cate J.W., Van der Poll T., Levi M., ten Cate H., and Van Deventer S.J.H. Cytokines: triggers of clinical thrombotic disease. Thromb Haemost 78 (1997) 415-419
20. Van Deventer S.J.H., Buller H.R., ten Cate J.W., Aarden L.A., Hack C.E., and Sturk A. Experimental endotoxinaemia in humans; analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 76 (1990) 2520-2526
21. Van der Poll T., Levi M., Buller H.R., Van Deventer S.J., de Boer J.P., Hack C.E., et al. Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 174 (1991) 729-732
22. Ardizzoia A., Lissoni P., Brivio F., Tisi E., Perego M.S., Grassi M.G., et al. Tumor necrosis factor in solid tumors: increased blood levels in the metastatic disease. J Biol Regul Homeost Agents 6 (1992) 103-107
23. Matanic D., Beg-Zec Z., Stojanovic D., Matakoric N., Fiego V., and Milevoj-Ribic F. Cytokines in patients with lung cancer. Scand J Immunol 57 (2003) 173-178
24. Aleman M.R., Santolaria F., Batista N., de La Vega M., Gonzalez-Reimers E., Milena A., et al. Leptin role in advanced lung cancer. A mediator of the acute phase response or a market of the status of nutrition?. Cytokine 19 (2002) 21-26